Eine Studie mit JNJ-1761981 bei Teilnehmern mit soliden Tumoren
Phase-1-Studie zur intratumoralen Verabreichung von JNJ-1761981 ER, einer Chemotherapie mit verlängerter Freisetzung, bei Teilnehmern mit soliden Tumoren
The purpose of Part 1 of this study is to determine a safe, tolerable, and feasible recommended total dose of intratumorally administered JNJ-1761981. The purpose of Part 2 of this study is to identify the optimal volumetric dose of JNJ-1761981 for the treatment of tumor lesions.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Intervention / Behandlung
Intervention / Behandlung
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Phase
Phase
- Phase 1
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Study Contact
- Telefonnummer: 844-434-4210
- E-Mail: Participate-In-This-Study1@its.jnj.com
Studienorte
-
-
Florida
-
Jacksonville, Florida, Vereinigte Staaten, 32224
- Rekrutierung
- Mayo Clinic in Florida
-
-
Minnesota
-
Rochester, Minnesota, Vereinigte Staaten, 55905
- Rekrutierung
- Mayo Clinic Rochester
-
-
New York
-
The Bronx, New York, Vereinigte Staaten, 10467
- Rekrutierung
- Montefiore Medical Center
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77030
- Rekrutierung
- MD Anderson Cancer Center
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion criteria:
- Part 1: Individuals with a diagnosis of locally advanced or metastatic disease (solid tumors except tumors of the central nervous system [CNS]) who have previously received available standard therapy and progressed, or cannot tolerate standard therapy, or for whom there is no standard of care per regional guidelines
- Part 2 Cohort A: Individuals with histologically or cytologically confirmed metastatic tumors of adenocarcinoma or squamous cell carcinoma histology, for which any platinum-based systemic regimen is considered a standard of care (per national comprehensive cancer network [NCCN] guidelines) and whose disease has progressed after standard therapy
- Eastern cooperative oncology group performance status (ECOG) performance status of Grade 0 or 1
- Part 2 Cohort A participants planned to receive optional cetrelimab (participants not meeting this criterion may still be enrolled in the study but cannot receive cetrelimab): Thyroid function laboratory values within normal range except for participants on thyroid hormone replacement therapy
- A participant of childbearing potential must practice at least 2 highly effective methods of contraception throughout the study and through 14 months (for women) and 11 months (for men) after the last dose of JNJ-1761981 or 5 months after the last dose of cetrelimab or other anti-PD(L)1 treatment, whichever is later
Exclusion criteria:
- Active symptomatic disease involvement of the central nervous system
- Prior or concurrent second malignancy (other than the disease under study) that due to natural history or treatment is likely to interfere with any study endpoints of safety or the antitumor activity of the study treatment(s)
- Active bleeding diathesis or requirement for therapeutic anticoagulation that cannot be interrupted or altered for procedures
- Known allergies, hypersensitivity, or intolerance to JNJ-1761981 or its excipients
- Lesions invading or adjacent to major blood vessels or other critical structures (for example, airways) not suitable for injection
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Nicht randomisiert
- Interventionsmodell: Sequenzielle Zuweisung
- Maskierung: Keine (Offenes Etikett)
Anzahl der Arme
Waffen und Interventionen
Teilnehmergruppe / ArmTeilnehmergruppe / Arm |
Intervention / BehandlungIntervention / Behandlung |
|---|---|
|
Experimental: Part 1: Dose Escalation
Participants will receive JNJ-1761981 intratumorally to determine a safe and tolerable total JNJ-1761981 dose. |
JNJ-1761981 will be administered intratumorally. |
|
Experimental: Part 2: Dose Expansion
Participants in Cohort A will receive JNJ-1761981 at specified volumetric doses. Participants who receive more than 1 dose of JNJ-1761981 may receive optional systemic therapy with cetrelimab at the discretion of the treating physician. |
JNJ-1761981 will be administered intratumorally. Cetrelimab will be administered intravenously.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Part 1: Number of Participants with Adverse Events (AE) by Severity
Zeitfenster: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version (v) 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants with Dose-Limiting Toxicities (DLTs)
Zeitfenster: Up to 28 days
|
High grade hematologic or non-hematologic toxicities with exceptions and/or toxicities leading to treatment discontinuation will be regarded as DLT. |
Up to 28 days
|
|
Part 1: Number of Participants with AEs by Severity Related to Delivery Device and/or Procedure
Zeitfenster: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 1: Number of Participants who Received Planned Total Dose per Level
Zeitfenster: Up to approximately 28 days
|
Number of participants who received planned total dose per level will be reported. |
Up to approximately 28 days
|
|
Part 2: Administered Tumor Response Rate
Zeitfenster: Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve complete response (CR) or partial response (PR). |
Up to approximately 2 years 10 months
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Parts 1 and 2: Plasma Concentration of Free and Total Platinum
Zeitfenster: Up to approximately 2 years 10 months
|
Plasma concentration of free and total platinum will be assessed. |
Up to approximately 2 years 10 months
|
|
Part 1: Administered Tumor Response Rate
Zeitfenster: Up to approximately 2 years 10 months
|
Administered tumor response rate is defined as the percentage of JNJ-1761981 administered lesions that achieve CR or PR. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Administered Tumor Duration of Response
Zeitfenster: Up to approximately 2 years 10 months
|
Administered tumor duration of response will be calculated among JNJ-1761981 administered lesions that responded from the date of initial documentation of lesion response to the date of first documented evidence of progression or start of subsequent anticancer treatment or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Objective Response Rate (ORR)
Zeitfenster: Up to approximately 2 years 10 months
|
ORR is defined as the percentage of participants who have best response of Complete Response (CR) or Partial Response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Disease Control Rate (DCR)
Zeitfenster: Up to approximately 2 years 10 months
|
DCR is defined as the percentage of participants who have achieved CR, PR, and stable disease for at least 4 weeks after study treatment was administered. |
Up to approximately 2 years 10 months
|
|
Parts 1 and 2: Duration of Response (DOR)
Zeitfenster: Up to approximately 2 years 10 months
|
DOR will be calculated among responders from the date of initial documentation of a response (first CR/PR) to the date of first documented evidence of progression according to RECIST v.1.1, or death due to any cause, whichever occurs first. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with Adverse Events (AE) by Severity
Zeitfenster: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Severity of AEs will be graded according to the NCI-CTCAE v 5.0. by using standard grades as follows: Grade 1: Mild; asymptomatic or mild symptoms; Grade 2: Moderate; minimal, local or noninvasive intervention indicated; Grade 3: Severe but not immediately life threatening; hospitalization or prolongation of hospitalization indicated; Grade 4: Life-threatening consequences; and Grade 5: Death related to AE. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants with AE by Severity Related to Delivery Device and/or Procedure
Zeitfenster: Up to approximately 2 years 10 months
|
An AE is any untoward medical occurrence in a participant administered a pharmaceutical (investigational or non investigational) product. An AE does not necessarily have a causal relationship with the treatment. Participants with AEs related to delivery device and/or procedure will be reported. |
Up to approximately 2 years 10 months
|
|
Part 2: Number of Participants who Received Planned Intratumoral Volumetric Dose
Zeitfenster: Up to approximately 2 years 10 months
|
Number of participants who received the planned intratumoral volumetric dose will be reported. |
Up to approximately 2 years 10 months
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Studienleiter: Johnson & Johnson Enterprise Innovation, Inc Clinical Trial, Johnson & Johnson Enterprise Innovation Inc.
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Tatsächlich)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- 1761981STM1001
- 1761981STM1001 (Andere Kennung: Janssen Research & Development, LLC)
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Beschreibung des IPD-Plans
The data sharing policy of Johnson & Johnson Innovative Medicine is available at www.innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu.
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .